Rise in Gallbladder Cancer Among Under-50s: Causes and Treatments
Gallbladder cancer is the latest form of cancer to be on the rise among people under 50, alongside bowel, breast, and lung ...
Medpage Today on MSN9 天
Primary Biliary Cholangitis Incidence and Prevalence Growing
Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...
NBC Los Angeles12 天
Woman, 23, had a ‘burning sensation' in her stomach. It was the first sign of a rare cancer
“I got an ultrasound, and it showed a solid mass.” Follow-up tests revealed Towle had bile duct cancer, also called ...
WebMD1 天
FDA Approves New Targeted Treatment for Biliary Tract Cancer
The FDA has approved a new drug, zanidatamab, for adults with advanced biliary tract cancer, or BTC. Marketed under the brand name Ziihera, it is a first-of-a-kind treatment for patients with ...
Today13 天
Woman, 23, had a ‘burning sensation’ in her stomach. It was the first sign of a rare cancer
In 2023, Sydney Towle, then 23, developed a bump on her abdomen that she could feel. When she exercised, she experienced a stinging in her stomach. Worried that she developed a hernia, Towle ...
Staten Island Advance1 天
After parents from Staten Island conduct desperate search for a donor, their baby undergoes ...
She was ultimately diagnosed with biliary atresia, a rare liver disease. According to the National Institutes of Health (NIH) ...
The Globe and Mail2 天
Cholangiocarcinoma Treatment Market 2034: Clinical Trials, Medication, EMA, PDMA, FDA ...
Cholangiocarcinoma, also known as bile duct cancer, is a rare but aggressive form of cancer originating in the bile ducts, ...
US FDA declines full approval for Intercept's liver disease drug
The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...
EurekAlert!3 天
FDA approves zanidatamab for biliary tract cancers with high HER2 levels
Learn more about a new treatment for biliary tract cancers with high levels of HER2. The drug zanidatamab has been approved by the FDA, thanks to a clinical trial co-led by MSK.